For the year ending 2025-12-31, NBY had $7,318K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -22,141 |
| Net income from discontinued operations, net of taxes | -11,081 |
| Stock-based compensation expense related to employee and director stock awards | 29 |
| Non-cash loss on extinguishment of secured convertible note | 0 |
| Non-cash expense incurred to obtain consent of secured convertible note holders | 0 |
| Non-cash loss (gain) on changes in fair value of warrant liability | 24,486 |
| Non-cash loss on changes in fair value of embedded derivative liability | 0 |
| Non-cash loss on modification of warrants | 0 |
| Non-cash right-of-use amortization | 140 |
| Impairment of long-lived assets | 854 |
| Amortization of debt discounts on convertible notes | 248 |
| Prepaid expenses and other current assets | 445 |
| Other assets | 85 |
| Accounts payable and accrued liabilities | -37 |
| Operating lease liabilities | -398 |
| Net cash used in operating activities, continuing operations | -8,430 |
| Net proceeds from issuance of preferred stock-Series DPreferred Stock | 3,786 |
| Net proceeds from issuance of preferred stock-Series EPreferred Stock | 2,049 |
| Cash payment pursuant to warrant exchange-Series FPreferred Stock | 525 |
| Proceeds from warrants exercise-Warrants And Prefunded Warrants | 852 |
| Proceeds from issuance of october 2025 pre-funded warrants | 5,946 |
| Proceeds from issuance of common stock and pre-funded warrants the 2024 public offering, net of issuance costs-Underwritten Registered Direct Offering | 0 |
| Proceeds from bridge loan-Bridge Loan | 0 |
| Payment on bridge note | 500 |
| Payments on secured convertible notes | 0 |
| Payments on warrants purchase | 2,001 |
| Payment on redemption of series f preferred stock-Series FPreferred Stock | 175 |
| Dividend paid | 4,817 |
| Cash debt issuance cost | 0 |
| Net cash provided by financing activities, continuing operations | 4,615 |
| Net decrease in cash, cash equivalents, and restricted cash, continuing operations | -3,815 |
| Net increase in cash and cash equivalents, discontinued operations | 11,133 |
| Net decrease in cash, cash equivalents and restricted cash, consolidated | 7,318 |
| Cash, cash equivalents and restricted cash, beginning of year | 907 |
| Cash, cash equivalents and restricted cash of continuing operations, end of year | 8,225 |
NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. (NBY)